Damon Kelsay, MD
Cardiovascular Disease · Rancho Mirage, CANPI 1750340667
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 69.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $398 and has fallen 73.8% since, to $104 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.
Across 57 payments — averaging $23.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$950
- Boston Scientific$139
- Edwards Lifesciences$94
- Siemens Medical Solutions USA, Inc.$74
- Endotronix, Inc.$26
- GE HealthCare$25
- plus $59 from 4 others
Across 23 payments — averaging $2818.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$65K
What the payments were for
- Food & beverage$1,365100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 42 | $950 |
| Boston Scientific | 6 | $139 |
| Edwards Lifesciences | 1 | $94 |
| Siemens Medical Solutions USA, Inc. | 1 | $74 |
| Endotronix, Inc. | 1 | $26 |
| GE HealthCare | 1 | $25 |
| Novartis | 1 | $22 |
| Merck | 1 | $22 |
| Medtronic | 1 | $14 |
| Travere Therapeutics, Inc. | 2 | $1 |
How this compares
$1,366 in reported general payments places this provider in the 40th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 522 | $565,807 |
| JardianceEmpagliflozin | 76 | $81,192 |
| XareltoRivaroxaban | 69 | $60,949 |
| MultaqDronedarone Hcl | 42 | $60,747 |
| Repatha SureclickEvolocumab | 58 | $41,509 |
| VascepaIcosapent Ethyl | 45 | $30,013 |
| MounjaroTirzepatide | 18 | $20,325 |
| BrilintaTicagrelor | 26 | $16,685 |
| OzempicSemaglutide | 17 | $16,157 |
| Praluent PenAlirocumab | 14 | $13,261 |
| Repatha SyringeEvolocumab | 13 | $12,700 |
| Metoprolol Succinate | 613 | $11,608 |
| Icosapent Ethyl | 33 | $10,460 |
| Atorvastatin Calcium | 883 | $9,316 |
| Ezetimibe | 343 | $8,509 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Rancho Mirage
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.